Table 4.
Prevalence of T790M mutation and c-MET amplification in Chinese patients with TKI-resistant NSCLC
| Study | Year | Technique |
T790M mutation
|
c-MET amplification
|
c-MET coexistent T790M
|
||
|---|---|---|---|---|---|---|---|
| TKI-naïve | TKI acquired-resistant | TKI-naïve | TKI acquired-resistant | TKI acquired-resistant | |||
| Chen et al65 | 2009 | HRM | 0% (0/53) | 48.3% (14/29) | 3.8% (2/53) | 10.3% (3/29) | 6.9% (2/29) |
| Chen et al56 | 2011 | FISH | 10.58% (22/208) | ||||
| Wu et al57 | 2011 | RT-PCR | 0.5% (6/1,261) | ||||
| He et al58 | 2013 | RT-PCR | 36.4% (24/33) | ||||
| Sequencing | 6.1% (2/33) | ||||||
| Su et al59 | 2012 | MALDI-TOF MS | 25.2% (27/107) | 83.3% (10/12) | |||
| Sequencing | 2.8% (3/107) | 33.3% (4/12) | |||||
| Ren et al21 | 2012 | Sequencing | 7.7% (8/104) | ||||
| Total | 2.8% (44/1,579) | 45.4% (54/119) | 9.2% (24/261) | 10.3% (3/29) | 6.9% (2/29) | ||
Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry; NSCLC, non-small-cell lung cancer; HRM, high resolution melting analysis; RT-PCR, reverse transcriptase polymerase chain reaction; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; TKI, tyrosine kinase inhibitor.